May 24, 2023 AlzeCure announces positive Phase IIa clinical study data in neuropathic pain with the non-opioid ACD440
April 19, 2023 AlzeCure gets an abstract on non-opioid ACD440 for neuropathic pain accepted at the EFIC 2023 Conference
March 30, 2023 AlzeCure presents new data at Alzheimer’s conference AD/PD on the potential disease-modifying effect of NeuroRestore ACD856
March 28, 2023 AlzeCure presents new data on its preventive treatment Alzstatin at the Alzheimer’s conference AD/PD 2023
March 13, 2023 AlzeCure achieves Last Patient Last Visit (LPLV) in its phase II clinical trial of the non-opioid ACD440 in neuropathic pain
January 31, 2023 Last patient included in AlzeCure’s Phase II clinical trial in peripheral neuropathic pain with the non-opioid ACD440
January 11, 2023 AlzeCure selects CD and enters next development phase with Alzstatin ACD680 against Alzheimer’s
